Semagacestat (LY450139) is a γ-secretase blocker with an IC50 of 15 nM. Semagacestat also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat blocks the enzyme γ-secretase, which (along with β-secretase) is responsible for APP proteolysis.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 50 mg/mL|
|Source||Science Advance (2017). semagacesta, Figure 6. (AbMole Bioscience)|
|Results||We showed that semagacestat was able to rescue levels of both NaV1.1 andNaV1.6, while LY2811376 only rescued those of NaV1.6 (one-way ANOVA for NaV1.1: F3,23 = 6.52, P = 0.0024; one-way ANOVA for NaV1.6: F3,23 = 5.911, P = 0.0038; Fig. 6). Therefore, beneficial effects of b- and g-secretase inhibitor treatments on the spatial object location task might be mediated, in part, by a rescue of the NaV levels, thereby restoring “normal” PV interneuron function|
|Source||Science Advance (2017). semagacesta, Figure 5. (AbMole Bioscience)|
|Results||In addition, we also confirmed that hippocampal b-CTF contents were decreased following the LY2811376 treatment but increased after the semagacestat treatment (one-sample t test against TgCRND8-vehicle: TgCRND8-LY2811376: t4 = 14.42, P = 0.0001; TgCRND8-semagacestat: t8 = 14.30, P < 0.0001). Given the distinct effect of LY2811376 and semagacestat treatments on both APP metabolite levels and cognitive performances, it is likely that different APP metabolites are responsible for the deficits of TgCRND8 mice in the spatial object location task and in the objectplace association task.|
Sci Adv. 2017 Feb 24;3(2):e1601068.
Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer’s disease
Semagacestat purchased from AbMole
|Related Gamma-secretase Products|
YO-01027 (Dibenzazepine, DBZ) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM for APPL and Notch cleavage, respectively.
LY900009 is a potent Notch inhibitor with IC50 of 0.27 nM.
LY3039478 is a novel and orally bioavailable inhibitor of Notch-1 intracellular domain (N1ICD) cleavage with IC50 of ~1 nM.
FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM.
LY2811376 is an orally available, non-peptidic β-secretase inhibitor with IC50 of 239 nM-249 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.